TRAIL-induced apoptosis of HL60 leukemia cells: two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFalpha but not to idarubicin and cytarabine.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Blood Cells, Molecules & Diseases

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.bcmd.2008.10.002PMID 19038561
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting NF-κB in hematologic malignancies

  2006cited by this paper
• Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL

  2006cited by this paper
• The molecular biology of TRAIL-mediated signaling and its potential therapeutic exploitation in hematopoietic malignancies.

  2006cited by this paper
• TRAIL resistance results in cancer progression: a TRAIL to perdition?

  2006cited by this paper
• NF-kappaB and IKK as therapeutic targets in cancer.

  2006cited by this paper
• TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma

  2006cited by this paper
• NF-κB and IKK as therapeutic targets in cancer

  2006cited by this paper
• Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3

  2006cited by this paper
• Targeting NF-kappaB in hematologic malignancies.

  2006cited by this paper
• IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy

  2005cited by this paper
• Mechanisms of resistance to TRAIL-induced apoptosis in cancer

  2005cited by this paper
• Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line.

  2005cited by this paper
• IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy.

  2005cited by this paper
• Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects.

  2005cited by this paper
• Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.

  2003cited by this paper
• Tumor necrosis factor (TNF)‐related apoptosis‐inducing ligand (TRAIL) and TNF‐α promote the NF‐κB‐dependent maturation of normal and leukemic myeloid cells

  2003cited by this paper
• Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells.

  2003cited by this paper
• Immune escape of tumors: apoptosis resistance and tumor counterattack

  2002cited by this paper
• TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors

  2002cited by this paper
• TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy

  2002cited by this paper
• Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB

  2001cited by this paper
• Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types

  2000cited by this paper
• FADD Is Required for DR4- and DR5-mediated Apoptosis

  2000cited by this paper
• Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

  1999cited by this paper
• Safety and antitumor activity of recombinant soluble Apo2 ligand.

  1999cited by this paper
• Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

  1998cited by this paper
• TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL

  1997cited by this paper
• Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

  1997cited by this paper
• Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family

  1997cited by this paper
• An antagonist decoy receptor and a death domain-containing receptor for TRAIL.

  1997cited by this paper
• The Receptor for the Cytotoxic Ligand TRAIL

  1997cited by this paper
• A novel receptor for Apo2L/TRAIL contains a truncated death domain.

  1997cited by this paper
• Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family*

  1996cited by this paper
• Identification and characterization of a new member of the TNF family that induces apoptosis.

  1995cited by this paper

• Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

  2021cites this paper
• RESENSITIZATION OF LEUKEMIA AND LYMPHOMA CELLS TO TRAIL-INDUCED APOPTOSIS MUDr

  2013cites this paper
• Resistance to TRAIL in mantle cell lymphoma cells is associated with the decreased expression of purine metabolism enzymes.

  2013cites this paper
• Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL).

  2013cites this paper
• Targeted ovarian cancer treatment: the TRAILs of resistance.

  2012cites this paper
• Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis

  2011cites this paper
• Identification of molecular targets for selective elimination of TRAIL‐resistant leukemia cells. From spots to in vitro assays using TOP15 charts

  2009cites this paper
• RETRACTED: Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

  year unknowncites this paper